Immunocore Holdings plc (NASDAQ:IMCR) Receives $65.64 Consensus PT from Analysts

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have received a consensus rating of “Moderate Buy” from the thirteen ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $65.64.

Several equities analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Immunocore in a research note on Monday, January 27th. UBS Group assumed coverage on shares of Immunocore in a research report on Thursday, October 24th. They issued a “sell” rating and a $24.00 target price for the company. Morgan Stanley reissued an “equal weight” rating and set a $35.00 price target (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Mizuho cut Immunocore from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $72.00 to $38.00 in a report on Monday, November 11th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $71.00 target price on shares of Immunocore in a report on Friday, January 10th.

Institutional Investors Weigh In On Immunocore

Several hedge funds have recently bought and sold shares of IMCR. Wellington Management Group LLP increased its stake in shares of Immunocore by 10.5% during the third quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock worth $219,430,000 after purchasing an additional 668,382 shares during the period. Primecap Management Co. CA grew its holdings in Immunocore by 26.7% in the 3rd quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock valued at $76,954,000 after buying an additional 520,950 shares in the last quarter. Millennium Management LLC increased its position in Immunocore by 124.4% during the 2nd quarter. Millennium Management LLC now owns 600,954 shares of the company’s stock worth $20,366,000 after buying an additional 333,167 shares during the period. Two Sigma Advisers LP lifted its holdings in shares of Immunocore by 65.6% during the third quarter. Two Sigma Advisers LP now owns 757,700 shares of the company’s stock worth $23,587,000 after buying an additional 300,200 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Immunocore by 25.0% in the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock valued at $17,007,000 after acquiring an additional 109,206 shares during the period. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Price Performance

Shares of NASDAQ IMCR opened at $30.59 on Thursday. The company has a fifty day moving average price of $30.44 and a 200 day moving average price of $32.93. The firm has a market cap of $1.53 billion, a PE ratio of -32.20 and a beta of 0.77. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore has a 1-year low of $27.69 and a 1-year high of $76.14.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.50. The business had revenue of $80.25 million during the quarter, compared to the consensus estimate of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. Immunocore’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period last year, the company earned ($0.59) earnings per share. Research analysts predict that Immunocore will post -0.94 earnings per share for the current fiscal year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.